Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump
Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results for its drug candidate to treat uterine fibroids.
The company said the trial showed its Proellex significantly reduced excessive menstrual bleeding in women with uterine fibroids. The company will now work with the US Food and Drug Administration (FDA) to plan a Phase III trial.
Repros Therapeutics is engaged in the development of new drugs to treat hormonal and reproductive system disorders.
Shares in the company closed up 18.7% at $2.67 Thursday on the Nasadq.
Pfizer and Myovant Science’s relugolix treatment to reduce menstrual blood loss in women with uterine …
Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders …